

August 24, 2020

HK inno.N Announces Publication of Results of Phase III Clinical Trial of Tegoprazan Targeting Gastric Ulcer

HK inno.N Corporation (Joint representative directors: Seok-Hee Kang and SangHyun Yoon, headquartered in Seoul, Korea; hereinafter called "HK inno.N") officially announced today that a paper on Phase III clinical trial of tegoprazan (K-CAB[®]), a drug for gastroesophageal reflux disease that RaQualia have licensed, has been published in an international medical journal.

The paper was published in AP&T (Alimentary Pharmacology & Therapeutics; ISSN: 0269-2813). The AP&T is included in the SCI (Science Citation Index), an academic database in which world-renowned top journals are registered.

The paper reports the results of Phase III clinical trial of tegoprazan for gastric ulcer in comparison with lansoprazole, a type of proton pump inhibitor (PPI). Both 50mg and 100mg groups of tegoprazan were non-inferior to 30 mg group of lansoprazole. There were no differences between groups regarding safety in this study.

In September 2010, RaQualia entered into an exclusive license agreement with HK inno.N for development, sales and manufacturing of tegoprazan in the East Asian region. RaQualia is eligible to receive royalties from HK inno.N. at a fixed rate on the sales of K-CAB[®] in Korea.

RaQualia and HK inno.N will continue to work together to maximize the value of tegoprazan. Both companies will strive to further contribute to expanding the treatment options for gastrointestinal diseases, improving patients' QOL (Quality of Life).

For further details, please refer to the HK inno.N official website at: http://www.inno-n.com/company/publicity_center/report_data/list.asp